Surmodics, Inc. (SRDX) EPS Estimated At $-0.01

April 19, 2018 - By Max Morgan

Surmodics, Inc. (NASDAQ:SRDX) LogoInvestors sentiment decreased to 0.69 in Q4 2017. Its down 0.25, from 0.94 in 2017Q3. It worsened, as 11 investors sold Surmodics, Inc. shares while 44 reduced holdings. 12 funds opened positions while 26 raised stakes. 11.07 million shares or 0.98% less from 11.18 million shares in 2017Q3 were reported.
Pdt Ptnrs invested in 12,500 shares. 5,370 were accumulated by Bnp Paribas Arbitrage. Schwab Charles Invest Mgmt holds 0% or 62,235 shares in its portfolio. Moreover, Blackrock Incorporated has 0% invested in Surmodics, Inc. (NASDAQ:SRDX). Meristem Limited Liability Partnership owns 8,196 shares. Assetmark has 4 shares for 0% of their portfolio. State Street Corp reported 0% stake. Pnc Finance Incorporated holds 0% or 167 shares. Wells Fargo & Mn has 28,209 shares. 46,660 are held by Royal Savings Bank Of Canada. Tiaa Cref Mgmt Ltd Com reported 57,934 shares stake. Gp Inc holds 10,283 shares or 0% of its portfolio. Tower Ltd (Trc) has 530 shares. The New York-based D E Shaw Co Inc has invested 0% in Surmodics, Inc. (NASDAQ:SRDX). Teton Incorporated holds 0.71% of its portfolio in Surmodics, Inc. (NASDAQ:SRDX) for 276,792 shares.

Since December 11, 2017, it had 0 insider buys, and 2 sales for $63,711 activity.

Analysts expect Surmodics, Inc. (NASDAQ:SRDX) to report $-0.01 EPS on April, 26.They anticipate $0.06 EPS change or 120.00 % from last quarter’s $0.05 EPS. After having $0.10 EPS previously, Surmodics, Inc.’s analysts see -110.00 % EPS growth. The stock decreased 1.41% or $0.55 during the last trading session, reaching $38.35. About 18,765 shares traded. Surmodics, Inc. (NASDAQ:SRDX) has risen 61.37% since April 19, 2017 and is uptrending. It has outperformed by 49.82% the S&P500.

Surmodics, Inc. (NASDAQ:SRDX) Ratings Coverage

Among 2 analysts covering Surmodics (NASDAQ:SRDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Surmodics had 2 analyst reports since February 28, 2018 according to SRatingsIntel. The company was upgraded on Wednesday, February 28 by Barrington Research.

Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland. The company has market cap of $506.09 million. It operates through two divisions, Medical Device and In Vitro Diagnostics. It has a 19175 P/E ratio. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.

Surmodics, Inc. (NASDAQ:SRDX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: